Rallybio Corporaton RLYB

$15.65 -0.15 (-0.95%)

Valuation

Market cap
85,066,000
Revenue TTM
$860,000
Net income TTM
$-8,980,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-1,044.19%
Debt to equity
0.00

Trading

Volume
23,300
Avg volume
19,830
Day's range
$15.51 – $15.95
Shares out
5,384,000
Stochastic %K
32%
Beta
-0.73
Analysts
Hold
Price target
$8.00

Price

Company profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the tre...

Show more

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Industry
Biotechnology
Sector
Healthcare
Phone
203 859 3820
Website
https://www.rallybio.com
Address
234 Church Street, New Haven, United States

Latest news

Stocktwits

focafoca99 Nov 6, 10:39 PM
$RLYB mentions postponement of its merger closing to after November 6 and a delay to the cash distribution payment and ex-dividend dates.
0 replies
Rayvio_News_Filter Nov 6, 10:27 PM
$RLYB · $ATXI 🤝 Rallybio Corporation and Avenzo Therapeutics postponed the closing of their merger, previously anticipated for November 6, 2026, to continue seeking listing approvals after certain share-listing conditions were not satisfied. Market-relevant event
0 replies
BigStockEnergy42069 Nov 3, 7:02 PM
$RLYB Declares Special Dividend to holders of record on Nov. 5th 2026. Recommended to hold stock through Nov. 6th for payout guarantee. Est. Special Cash Dividend per share is $13.56 (based on $16.65 stock price; Dividend = (Current Stock Price) x .954). Not sure how y'all think, but I personally love free money 🤷‍♂️
0 replies
KSA_Aaron Oct 26, 9:16 PM
$RLYB - Did anyone catch the special dividend news? I believe I heard $13.50, which means greater than 25% of last 5 days avg share price, so can be paid in shares. This likely means that a S-1 shelf offering would be waiting. Looking for details....
0 replies
SqueezeSpecs Sep 27, 10:47 AM
$RLYB: Rallybio is moving toward its planned merger with Avenzo Therapeutics, which would create an oncology-focused publicly traded biotech. Rallybio shareholders are expected to own about 2.8% of the combined company under the current filing. ("rallybio(dot)com" (https://investors.rallybio.com/news-releases) ) RLYB closed Friday at $16.62, essentially flat on the day. The company also reported a $50M termination fee from the previously proposed Candid Therapeutics transaction, adding to its cash resources ahead of the Avenzo merger.
0 replies
CamelMoneyMaker Sep 2, 1:24 AM
I rarely trade penny stocks but $FBIO $FMFC $RLYB these tickers passed the “Graham-NCAV test” Worth keeping them on your watchlist
0 replies
Toni1976 Aug 14, 3:37 AM
$RLYB I’m bullish on RLYB here. The company has demonstrated encouraging clinical data for RLYB116, and the upcoming Avenzo transaction brings a $215M financing and a pipeline of four clinical-stage oncology programs. With the stock still at a relatively small market cap, I see significant asymmetric upside if the transaction closes and the pipeline delivers. High risk, but the potential reward makes RLYB very attractive at these levels
0 replies
Toni1976 Aug 10, 2:33 PM
$RLYB I’m bullish on RLYB because of the strong clinical potential, meaningful unmet need, and the possibility of significant value creation if the upcoming catalysts deliver. The risk is high, but so is the upside.
0 replies